NCT04451850View on ClinicalTrials.gov

HRV as a Marker of Treatment Response in PAH Arterial Hypertension

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Pulmonary Arterial Hypertension
Interventions
OTHER

Noninvasive actigraphy monitor

Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.

Trial Locations (1)

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

University of Cincinnati

OTHER